Outcome-Adaptive Randomization: Is It Useful?KORN, Edward L; FREIDLIN, Boris.Journal of clinical oncology. 2011, Vol 29, Num 6, pp 771-776, issn 0732-183X, 6 p.Article

Monitoring for Lack of Benefit : A Critical Component of a Randomized Clinical TrialFREIDLIN, Boris; KORN, Edward L.Journal of clinical oncology. 2009, Vol 27, Num 4, pp 629-633, issn 0732-183X, 5 p.Article

Evaluation of randomized discontinuation designFREIDLIN, Boris; SIMON, Richard.Journal of clinical oncology. 2005, Vol 23, Num 22, pp 5094-5098, issn 0732-183X, 5 p.Article

Adaptive signature design : An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patientsFREIDLIN, Boris; SIMON, Richard.Clinical cancer research. 2005, Vol 11, Num 21, pp 7872-7878, issn 1078-0432, 7 p.Article

Should the median test be retired from general use?FREIDLIN, Boris; GASTWIRTH, Joseph L.The American statistician. 2000, Vol 54, Num 3, pp 161-164, issn 0003-1305Article

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent TherapiesKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2439-2442, issn 0732-183X, 4 p.Article

Biomarker-adaptive threshold design : A procedure for evaluating treatment with possible biomarker-defined subset effectWENYU JIANG; FREIDLIN, Boris; SIMON, Richard et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 13, pp 1036-1043, issn 0027-8874, 8 p.Article

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials : The National Cancer Institute Cooperative Group Experience From 1990 to 2005KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2009, Vol 27, Num 10, pp 1712-1721, issn 0732-183X, 10 p.Article

Robust genomic control for association studiesGANG ZHENG; FREIDLIN, Boris; GASTWIRTH, Joseph L et al.American journal of human genetics. 2006, Vol 78, Num 2, pp 350-356, issn 0002-9297, 7 p.Article

A model to select regimens for Phase III trials for patients with advanced-stage non-small cell lung cancerFREIDLIN, Boris; BREATHNACH, Oscar S; JOHNSON, Bruce E et al.Clinical cancer research. 2003, Vol 9, Num 3, pp 917-922, issn 1078-0432, 6 p.Article

Choice of scores in trend tests for case-control studies of candidate-gene associationsGANG ZHENG; FREIDLIN, Boris; ZHAOHAI LI et al.Biometrical journal. 2003, Vol 45, Num 3, pp 335-348, issn 0323-3847, 14 p.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Phase III Clinical Trials That Integrate Treatment and Biomarker EvaluationFREIDLIN, Boris; ZHUOXIN SUN; GRAY, Robert et al.Journal of clinical oncology. 2013, Vol 31, Num 25, pp 3158-3161, issn 0732-183X, 4 p.Article

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5197-5201, issn 0732-183X, 5 p.Article

Randomized clinical trial design for assessing noninferiority when superiority is expectedFREIDLIN, Boris; KORN, Edward L; GEORGE, Stephen L et al.Journal of clinical oncology. 2007, Vol 25, Num 31, pp 5019-5023, issn 0732-183X, 5 p.Article

Preliminary data release for randomized clinical trials of noninferiority : A new proposalKORN, Edward L; HUNSBERGER, Sally; FREIDLIN, Boris et al.Journal of clinical oncology. 2005, Vol 23, Num 24, pp 5831-5836, issn 0732-183X, 6 p.Article

Randomized Phase II Trial Designs With BiomarkersFREIDLIN, Boris; MCSHANE, Lisa M; POLLEY, Mei-Yin C et al.Journal of clinical oncology. 2012, Vol 30, Num 26, pp 3304-3309, issn 0732-183X, 6 p.Article

Methods for assessing reproducibility of clustering patterns observed in analyses of microarray dataMCSHANE, Lisa M; RADMACHER, Michael D; FREIDLIN, Boris et al.Bioinformatics (Oxford. Print). 2002, Vol 18, Num 11, pp 1462-1469, issn 1367-4803, 8 p.Article

Phase ii clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancerJACKMAN, David M; YEAP, Beow Y; FREIDLIN, Boris et al.Journal of clinical oncology. 2007, Vol 25, Num 7, pp 760-766, issn 0732-183X, 7 p.Article